Soares Adinei Abadio, Dos Santos Helamã Moraes, Domann Keyllor Nunes, Alves Natália Pratis Rocha, Böhm Bernardo Ribeiro, Haack Carolina Maliska, Pretto Kailane Paula, Guimarães Emily Sanini, Rocha Guilherme Francisquini, de Paula Igor Rodrigues, de Alcântara Guimarães Lucas Efraim, de Ávila Pessoa Harlan Cleyton, Rodrigues Robison David, Dalagnol Angela Makeli Kososki, da Cunha Marcelo Lemos Vieira, de Resende E Silva Débora Tavares
Department of Medicine, Federal University of Fronteira Sul, Chapecó, Santa Catarina, Brazil.
Department of Graduate Nursing, Federal University of Fronteira Sul, Chapecó, Santa Catarina, Brazil.
Purinergic Signal. 2024 Oct 1. doi: 10.1007/s11302-024-10053-8.
Purine nucleotides and nucleosides play critical roles in various pathological conditions, including tumor cell growth. Adenosine triphosphate (ATP) activates pro-tumor receptors, while adenosine (ADO) is a potent immunosuppressant and modulator of cell growth. This study aims to analyze the purinergic actions of ATP and its metabolites, associated enzymes, and P1 or P2 class receptors in primary central nervous system tumors. Additionally, we sought to correlate the levels of nucleosides and the density of P1, P2X, and P2Y receptors in cells with tumor progression. The results indicate that purinergic signaling depends on the receptor concentration and signaling molecules specific to each cell type, tissue, and tumor histology. The purinergic system may function as either a tumor-promoting agent or an antitumor factor, depending on the microenvironmental conditions and the concentrations of receptors and their respective activators. Notably, ATP emerges as the most significant extracellular signal, capable of being converted into other cellular stimulators pertinent to neoplasms, such as adenosine diphosphate, adenosine monophosphate, adenosine, and inosine. Consequently, a cascade of responses to these stimuli promotes tumor development, cell division, and metastasis. Purine nucleotides in central nervous system tumors are pivotal in cellular responses in glioblastoma multiforme, vestibular schwannoma, medulloblastoma, adenomas, gliomas, meningiomas, and pineal tumors. These findings hold the potential for developing novel therapeutic strategies and aiding in therapeutic management.
嘌呤核苷酸和核苷在包括肿瘤细胞生长在内的各种病理状况中发挥着关键作用。三磷酸腺苷（ATP）激活促肿瘤受体，而腺苷（ADO）是一种强效免疫抑制剂和细胞生长调节剂。本研究旨在分析原发性中枢神经系统肿瘤中ATP及其代谢产物、相关酶以及P1或P2类受体的嘌呤能作用。此外，我们试图将细胞内核苷水平以及P1、P2X和P2Y受体的密度与肿瘤进展相关联。结果表明，嘌呤能信号传导取决于受体浓度以及每种细胞类型、组织和肿瘤组织学特有的信号分子。根据微环境条件以及受体及其各自激活剂的浓度，嘌呤能系统可能充当促肿瘤剂或抗肿瘤因子。值得注意的是，ATP成为最重要的细胞外信号，能够转化为与肿瘤相关的其他细胞刺激物，如二磷酸腺苷、一磷酸腺苷、腺苷和肌苷。因此，对这些刺激的一系列反应促进肿瘤发展、细胞分裂和转移。中枢神经系统肿瘤中的嘌呤核苷酸在多形性胶质母细胞瘤、前庭神经鞘瘤、髓母细胞瘤、腺瘤、胶质瘤、脑膜瘤和松果体肿瘤的细胞反应中起关键作用。这些发现具有开发新治疗策略和辅助治疗管理的潜力。
